Hellesylt E - Search Results

1

MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions.

Davidson B, Stavnes HT, Hellesylt E, Hager T, Zeppa P, Pinamonti M, Wohlschlaeger J. Davidson B, et al. Among authors: hellesylt e. Hum Pathol. 2016 Jan;47(1):104-8. doi: 10.1016/j.humpath.2015.08.020. Epub 2015 Sep 25. Hum Pathol. 2016. PMID: 26520416

2

Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.

Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B. Slipicevic A, et al. Among authors: hellesylt e. Hum Pathol. 2009 Apr;40(4):527-37. doi: 10.1016/j.humpath.2008.10.003. Epub 2009 Jan 3. Hum Pathol. 2009. PMID: 19121847

3

Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.

Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J. Hetland TE, et al. Among authors: hellesylt e. Hum Pathol. 2011 Jul;42(7):1019-26. doi: 10.1016/j.humpath.2010.10.025. Epub 2011 Feb 11. Hum Pathol. 2011. PMID: 21315408

4

VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival.

Davidson B, Rosenfeld YB, Holth A, Hellesylt E, Tropé CG, Reich R, Yisraeli JK. Davidson B, et al. Among authors: hellesylt e. Hum Pathol. 2014 Jul;45(7):1520-8. doi: 10.1016/j.humpath.2014.03.005. Epub 2014 Mar 27. Hum Pathol. 2014. PMID: 24814803

5

The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.

Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP. Davidson B, et al. Among authors: hellesylt e. Hum Pathol. 2015 Jan;46(1):1-8. doi: 10.1016/j.humpath.2014.10.004. Epub 2014 Oct 16. Hum Pathol. 2015. PMID: 25455994

6

HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.

Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, Reich R. Davidson B, et al. Among authors: hellesylt e. Hum Pathol. 2016 Feb;48:95-101. doi: 10.1016/j.humpath.2015.09.027. Epub 2015 Oct 22. Hum Pathol. 2016. PMID: 26640230

7

Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA. Slipicevic A, et al. Among authors: hellesylt e. Gynecol Oncol. 2014 Oct;135(1):118-24. doi: 10.1016/j.ygyno.2014.07.102. Epub 2014 Aug 2. Gynecol Oncol. 2014. PMID: 25093290

8

Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma.

Davidson B, Hellesylt E, Holth A, Danielsen HE, Skeie-Jensen T, Katz B. Davidson B, et al. Among authors: hellesylt e. Virchows Arch. 2017 Sep;471(3):355-362. doi: 10.1007/s00428-017-2172-5. Epub 2017 Jun 22. Virchows Arch. 2017. PMID: 28643014

9

TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.

Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Tropé CG, Dørum A, Reich R. Gutgold N, et al. Among authors: hellesylt e. Virchows Arch. 2017 Jun;470(6):665-678. doi: 10.1007/s00428-017-2127-x. Epub 2017 Apr 21. Virchows Arch. 2017. PMID: 28432432

10

Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma.

Davidson B, Bjørnerem M, Holth A, Hellesylt E, Hetland Falkenthal TE, Flørenes VA. Davidson B, et al. Among authors: hellesylt e. Gynecol Oncol. 2018 Jul;150(1):136-142. doi: 10.1016/j.ygyno.2018.05.007. Epub 2018 May 24. Gynecol Oncol. 2018. PMID: 29804637

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters